valu usd unless otherwis note
four real-tim data point add encourag
view upgrad share straight forward thesi
expect higher demand privat label over-the-counter drug busi
amidst downturn ii expect privat label share gain
econom downturn side stock lag
latest ralli continu expect share favor
diverg still buy rate two addit upgrad recent day
iri data indic robust growth cold/cough/allergi over-the-counter
growth ytd notabl four week end march
yoy reemphas view prgo consum over-the-counter busi
stabl potenti see boost addit privat
label over-the-counter medicin histor taken market share past
econom downturn could case come current
pandem close market share us privat label
retail chain read-through also encourag earlier week
larg chain walgreen announc
addit hire across countri respons
effort support demand across broader busi
believ sale over-the-counter drug higher level consist iri
data investor confer appear support
notion think extens flu season
sever variabl relat impact
take csca-onli revenu csci could also benefit
boost strong cough/cold/flu season flat-lin
would see million revenu upsid
basi point growth
care act trillion coronaviru aid relief econom
secur act bring favor chang over-the-counter market unexpect
add emerg relief bill includ provis would allow
fda approv over-the-counter medicin without go full notic
comment rule make would provid fda flexibl
streamlin process speed new approv bill also creat
incent innov offer month exclus new
over-the-counter drug could potenti benefit given new push
innov over-the-counter
could benefit sustain step e-commerc
structur growth e-commerc over-the-counter drug sale continu
learn experi amidst brick mortar visit
hurdl busi million global grow
importantli singl buyer price pressur
concern growth remaind spread
among tradit custom direct-to-consum said
good partner basic line exclus infant
formula
dissemin produc price prior trade day market close estimate unless otherwis note
stabl long-term outlook well posit current
unknown environ attract rel posit
see demand underli product unlik
materi impact move econom downturn
recess lower price price store brand portfolio
over-the-counter product potenti pick market share past
downturn final view tax overhang like lift
year improv financi flexibl
driver thesi
organ csca growth like remain lower level
near term base busi eros like remain
overal see stabl revenu growth
csci oper margin expans continu
next year offer addit ep support
gener rx still expect separ time
seem unclear assum remain consolid
valuat like dictat valu market
place remain-co consum busi
think rel see appreci
given rel posit current downturn
upsid risk success separ sale rx
drive premium asset acceler new launch
activ across over-the-counter rx fda approv new larg
over-the-counter categori switch favor quicker-than-
expect resolut irish tax disput ir nopa
downsid risk slowdown core csca revenu
impact overal busi assum
greater dis-synergy/dilut rx separ
expect unfavor outcom irish us tax
upcom potenti catalyst updat around spin
potenti bolt-on accret use
capit clariti tax issu
bloomberg capit market estim upside/downside/target
base-cas scenario see stock impli
price-to-earnings ep
low-single-digit growth csca driven larg
recent oral self-car acquisit annual flattish
declin oper margin across platform near-
term driven step-up invest return growth
time
debt pay-down excess cash share repurchas
linger overhang irish tax disput ir nopa
weigh share price
upsid case scenario see stock impli
price-to-earnings ep
mid-single-digit better organ revenu growth
oper margin expans across platform
debt pay-down excess cash re-introduc accret
favor resolut irish ir tax disput
downsid scenario see stock impli
price-to-earnings pro forma ep
step-up invest fail pay contribut lower
oper margin time
model
particularli rx
exhibit segment build
 segment build self-car ranir sale million synergi exp gross distribut oper oper per management flattish margin bc investmentssal growth stop declin revers futuredistribut sg mix profit mix incom mix self-car inclus ranir intenational gross ranir lower gm intenational rest biz neutral omdistribut oper oper sale growth ranir gmdistribut sg expans next year sale mix profit mix incom mix
exhibit segment build cont
 segment build y/i growth vs gross distribut oper oper y/i growth vs meaning declin sale growth sg mix profit mix incom mix corpor cost across platform
exhibit forecast
 incom self-car consum self-car prescript y/i growth vs total revenu net sale growth organ growth growth y-i growth driven acquisitionscost total gross profit gross portion invest dsg oper incom excl invest close target oper incom incom tax provis incom net incom ep non-gaap adj dilut ep share fulli dilut share ebitda ebitda analysi growth beyondadjust net margin expens net incom pharmaceuticals/specialti
price target base blend price-to-earnings ev/ebitda multipl use cy
estim assum multipl respect taken histor
averag global consum multipl price-to-earnings ev/ebitda made adjust
base company-specif attribut private-label discount earn momentum gener
busi discount litig risk collect result valuat discount
impli return price target support outperform rate
risk rate price target
organ revenu growth consum self-car america segment soften due
weaker-than-expect over-the-counter market growth greater-than-expect price eros
delay fda approv gener drug applic result declin revenu and/
margin rx segment
unexpect meaning competit entri us store brand over-the-counter rx busi
lead store-brand over-the-counter manufactur us market share compani
also particip pharmaceut market domest intern
omega deal ad ex-u exposur often compar larg global
manufactur realiti direct comp given diversifi busi model
encompass consum healthcar brand consum healthcar rx compani
acquir brought lower tax structur royalti stream tysabri sold
royalti pharma set platform intern expans
